Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S468000
Reexamination Certificate
active
07053113
ABSTRACT:
The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
REFERENCES:
patent: 2968557 (1961-01-01), Burgandt et al.
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4642309 (1987-02-01), Michel et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5124347 (1992-06-01), Connor et al.
patent: 5196446 (1993-03-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5389661 (1995-02-01), Sircar et al.
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5849710 (1998-12-01), Battistini et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6133305 (2000-10-01), Tang et al.
patent: 6451838 (2002-09-01), Moon et al.
patent: 6482848 (2002-11-01), Moon et al.
patent: 6710067 (2004-03-01), Moon et al.
patent: 286870 (1967-05-01), None
patent: 2012634 (1991-09-01), None
patent: 2159360 (1971-11-01), None
patent: 2159361 (1971-11-01), None
patent: 2159362 (1971-11-01), None
patent: 2159363 (1971-11-01), None
patent: 2321656 (1973-04-01), None
patent: 3426419 (1986-01-01), None
patent: 0351213 (1990-01-01), None
patent: 0252713 (1990-09-01), None
patent: 0525472 (1993-02-01), None
patent: 0632102 (1995-01-01), None
patent: 0662473 (1995-07-01), None
patent: 0769947 (1997-05-01), None
patent: 0788890 (1997-08-01), None
patent: 0934931 (1999-08-01), None
patent: 1082305 (2001-03-01), None
patent: 809691 (1959-03-01), None
patent: 835473 (1960-05-01), None
patent: 1398224 (1965-03-01), None
patent: 1599772 (1970-08-01), None
patent: 2689397 (1993-10-01), None
patent: 6239564 (1987-02-01), None
patent: 6229570 (1987-07-01), None
patent: 63141955 (1988-06-01), None
patent: 558894 (1993-03-01), None
patent: WO 91/13055 (1991-09-01), None
patent: WO 92/07830 (1992-05-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 93/01182 (1993-01-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 95/01349 (1995-01-01), None
patent: WO 95/17181 (1995-06-01), None
patent: WO 96/22976 (1995-08-01), None
patent: WO 96/00226 (1996-01-01), None
patent: WO 96/16964 (1996-06-01), None
patent: WO 96/32380 (1996-10-01), None
patent: WO 96/40116 (1996-12-01), None
patent: WO 97/25986 (1997-07-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 98/24432 (1998-06-01), None
patent: WO 98/38984 (1998-09-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 99/10325 (1999-03-01), None
patent: WO 99/52869 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/65869 (1999-12-01), None
patent: WO 00/08202 (2000-02-01), None
patent: WO 00/35906 (2000-06-01), None
patent: WO 00/35908 (2000-06-01), None
patent: WO 00/35909 (2000-06-01), None
patent: WO 00/38519 (2000-07-01), None
patent: WO 00/56709 (2000-09-01), None
patent: WO 01/60814 (2001-08-01), None
patent: WO 01/90104 (2001-11-01), None
Andreani et al., “Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones,”Anticancer Research16:3585-3588 (1996) 8 Elsevier, Paris.
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Eur. J. Med. Chem.25:187-190 (1990).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,”Eur. J. Med. Chem.28:653-657 (1993) 8 Elsevier, Paris.
Andreani et al., “Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,”Eur. J. Med. Chem.27:167-170 (1992) 8 Elsevier, Paris.
Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Eur. J. Med. Chem.32:919-924 (1997)8 Elsevier, Paris.
Andreani et al., “Synthesis of lactams with potential cardiotonic activity,”Eur. J. Med. Chem.28:825-829 (1993).
Andreani et al., “In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,”Arzneimittel-Forschung Drug Research48:727-729 (1998) 8.
Bahner and Brotherton, “9-(4-Aminobenzylidene)fluorenes,”J. Med. Chem.12:722-723 (1969).
Bahner et al., “Benzylideneindenes with Oxygen Attached to the Indene Ring,”J. Med. Chem.12:721-722 (1969).
Bamfield et al., “Diels-Alder Reactions of Oxindolylideneacetone,”J. Chem. Soc.(C) 1028-1030 (1966) 8.
Borsche et al., “Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.,”Liebigs Ann. Chem.550:160-174 (1941).
Buzzetti et al., “Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,”II Farmaco48:615-636 (1993).
Chatten et al., “Substituted Oxindoles. Part VI. Polarographic Reduction of Substitutedtrans-3-Benzylideneindol-2(3H)-ones,”J. Chem. Soc. Perkin II:469-473 (1973).
Coda et al., “(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,”J. Chem. Soc. Perkin Trans. II:615-619 (1984).
Coda et al., “3-(4-methylbenzilidene)-1,3-dihydroindol-2-one,”Journal of the Chemical Society, Perkin Transactions 24:615-620 (1984) Database Crossfire, Beilstein Reference No. 6-21.
Decodts et al., “Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,”Eur. J. Med. Chem18: 107-111 (1983).
Desimoni et al., “Catalysis with Inorganic Cations. V1Intramolecular Hetero Diels-AlderversusEne Reactions: Effect of Magnesium perchlorate on Chemoselectivity,”Tetrahedron52(36) 12009-12018 (1196) 8 Pergamon.
Elliott and Rivers, “Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride,”J. Med. Chem.29:2438-2440 (1964).
Elliott et al., “1-methyl-2-(3-oxindolidenmethyl)-pyridinium,”Journal of Organic Chemistry29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.
Gazit et al., “Tyrphostins. 2. Heterocyclic and β-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2
eu Tyrosine Kinases,”J. Med. Chem.34:1896-1907 (1991) copyright Am. Clem. Soc.
Hirao et al., “Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones,”Tetrahedron Letters36(35) 1995 8Pergamon.
Hodges et al., “Chemical and biological properties of some oxindolidyl-3-methines,”Canadian J. Chemistry46:2189-2194 (1968).
Howard, Harry R., “Lactam Derivatives,” U.S. Appl. No. 60/015,134.
Howard et al., “Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids,”Eur. J. Med. Chem.27:779-789 (1992) 8 Elsevier, Paris.
Katritzky et al., “Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues,”J. Heterocyclic Chem.25:1287-1292 (1988).
Kobayashi et al., “Anti-tumor Activity of Indole Derivatives,”Yakugaku Zasshi97:1033-1039 (1977).
Kovac and Stetinova, “Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles,”Chem. rvesu30:484-492 (1976).
Levitzki and Gazit, “Tyrosine Kinase Inhibition: An Approach to Drug Development,”Science267:1782-1788 (1995).
Mariani et al., “Inhibition of angiogenesis by FCE 26806, a potent tyrosin
Gao Ping
Moon Malcolm Wilson
Morozowich Walter
Tang Peng Cho
Anderson Rebecca
Hua Ye
Pharmacia & Upjohn Company LLC
Prodnuk Stephen D.
Saeed Kamal A.
LandOfFree
Mannich base prodrugs of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mannich base prodrugs of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mannich base prodrugs of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554085